Latest Posts
Adaptive Clinical Trials: What Are They and Why Do They Matter?
Traditional clinical trials follow a fixed plan from start to finish. Adaptive designs let trials change course based on data collected along the way, making them faster, more efficient, and more ethical.
Adverse events and safety monitoring in clinical trials, explained
Every clinical trial carries risk. Adverse event reporting, independent safety boards, and stopping rules are the system that tracks problems early and protects the volunteers who make research possible.
AI in Clinical Trials: How Machine Learning Is Transforming Drug Development
Machine learning is moving into clinical trials: faster patient recruitment, earlier safety signals, and synthetic control arms. Here is how regulators are reacting and what still stands in the way.
Biomarkers and Surrogate Endpoints in Clinical Trials, Explained
Clinical trials cannot always wait years to see who lives longer or feels better. Biomarkers and surrogate endpoints measure success earlier — but they can lie.
What Does a Clinical Research Associate (CRA) Actually Do?
The CRA is the sponsor's eyes and ears at the clinical trial site. Here's what the job actually involves, from source data verification to drug accountability.
Clinical Research vs Medical Care: The Difference You Must Understand
When you see a doctor, the goal is to treat you. When you join a clinical trial, the goal is to generate knowledge for future patients. Here is why that distinction matters, and the questions you should ask before enrolling.
Clinical Trial Compensation: How Much Should You Pay Someone to Participate?
How much should clinical trial participants be paid? Pay too little and enrollment stalls; pay too much and you risk coercion. This article breaks down reimbursement, payment, and incentives, and the ethical rules that separate fair compensation from undue influence.
Clinical Trial Data Management: How Data Is Collected, Cleaned, and Locked
Before a statistician touches the numbers, data managers collect, verify, clean, and lock every data point in a clinical trial. This is how the machinery works, from eCRFs and edit checks to database lock.
Clinical Trial Phases Explained: From First Dose to Pharmacy Shelf
A new medicine passes through four gates before reaching patients. Here's what actually happens inside each phase, from first-in-human safety testing to post-market surveillance.
Clinical Trial Registries: Why Transparency Matters
Before 2007, much of clinical research operated behind a curtain. Public registries like ClinicalTrials.gov changed that. Here's how they work and why they matter.
Clinical trials in children: why kids are not small adults
Children's bodies process drugs differently, they cannot legally consent, and they are still growing. Pediatric trials have their own regulations, consent rules, and trial designs, and they have transformed childhood survival rates.
The CRO Industry: How Contract Research Organizations Run Clinical Trials
Contract research organizations manage most of the world's clinical trials. Here is how the CRO industry works, who the major players are, and where the market is heading.
Data monitoring committees: the guardians of clinical trial safety
Data monitoring committees are independent experts who watch over a trial's safety data while it is still running. Here is how they work, when they are needed, and why independence is everything.
Day in the Life of a Clinical Research Coordinator: What CRCs Actually Do
Clinical research coordinators are the people who make trials actually work at the site: consent, labs, source data verification, regulatory binders, and retention. Here is what a CRC's day really looks like.
The Declaration of Helsinki: The Ethical Foundation of Medical Research
One document guides the ethics of nearly every clinical trial on earth. Born from the Nazi doctors' trial, revised seven times, and still controversial in places, the Declaration of Helsinki is worth understanding.
Digital Health Technologies in Clinical Trials: Wearables, Sensors, and Smarter Data
Wearables, sensors, and patient apps are moving clinical trials out of the clinic and into daily life. Here is how digital health technologies work in research, what regulators require, and where the data goes.
Drug Development Pipeline Explained: From Lab to Pharmacy Shelf
It takes 10 to 15 years and over a billion dollars to bring one new drug to patients, and most candidates never make it. Here is the full pipeline, from discovery and preclinical testing through clinical trials, FDA review, and post-market monitoring.
ePRO in Clinical Trials: Patient-Reported Outcomes From Home
Electronic patient-reported outcomes, or ePRO, let trial participants record symptoms and quality of life from home instead of recalling them at clinic visits. This article explains how ePRO works, why compliance beats paper diaries, and what the FDA says about it.
Exception from Informed Consent in Emergency Research: What EFIC Is and How It Works
When a patient is in cardiac arrest or a severe trauma, there is no time for a consent conversation. EFIC allows researchers to enroll these patients in emergency studies without prior consent, under strict federal rules. This article explains when EFIC applies and the safeguards that surround it.
The FDA drug approval process: from phase III to pharmacy
A drug only reaches the pharmacy after years of discovery, preclinical testing, three phases of clinical trials, and a thorough FDA review. Here is how the process actually works, from phase III to the NDA to the shelf.
FDA Form 483: What It Is, How to Respond, and How to Prevent It
A Form FDA 483 lists what an FDA investigator observed during an inspection. It is not a final finding, but how you respond can decide whether the matter ends there or escalates to a warning letter. Here is what sites need to know.
Financial Disclosure in Clinical Trials: What Form FDA 3455 Really Covers
Financial conflicts of interest can bias a clinical trial's results, which is why the FDA requires disclosure under 21 CFR Part 54. This article explains the thresholds, who must disclose, and how Form FDA 3455 keeps the process honest.
Generic vs brand-name drugs: what's the real difference?
Generics have the same active ingredient at 80 percent less cost, but they are approved through a different pathway built on bioequivalence studies. Here is how that works, and why some patients still notice a difference.
Geriatric Trials: Why Older Adults Are Left Out of Clinical Research
Adults over 65 take the most prescription drugs of any age group, yet they are often excluded from the trials that test those drugs. This article explains why older adults are underrepresented in clinical research, what regulators say about it, and how trial design can fix the gap.
Global Supply Chain in Clinical Trials: How Drugs Reach Patients at Sites
Investigational drugs travel from manufacturer to trial sites through a tightly tracked chain: GMP manufacturing, blinded packaging, cold-chain shipping, and full drug accountability. Here is how it all works.
Health Equity in Clinical Research: Why Diverse Trials Make Better Medicine
When clinical trials do not reflect the people who will use the treatments, the results cannot be trusted for everyone. This article covers the history, the barriers, the regulatory push for diversity, and the models that work.
How Much Does a Clinical Trial Actually Cost to Run?
Phase 3 trials can cost hundreds of millions of dollars. Here is where clinical trial money actually goes, from site reimbursements to hidden costs like protocol amendments.
How to Find and Evaluate Clinical Trials After a Diagnosis
After a serious diagnosis, finding a legitimate clinical trial can feel overwhelming. This article explains how to search ClinicalTrials.gov, read eligibility criteria, ask your doctor the right questions, and spot the red flags of a questionable trial.
Informed Consent in Clinical Trials: Before You Sign, Watch This
Informed consent is a process, not a piece of paper. Here is what the three pillars of consent mean, the eight elements every consent form must include, the myths that trip people up, and the questions to ask before you sign.
Who Protects You in a Clinical Trial? Meet the IRB
Before any trial can enroll its first volunteer, an independent committee must say yes. The institutional review board reviews the science, the consent form, and the risks — and keeps watching after approval.
Interim analyses: when should a clinical trial stop early?
Interim analyses are pre-planned looks at trial data that can stop a study early for safety, futility, or overwhelming efficacy. The catch: every look inflates the false positive rate, so the rules must be set in advance.
Investigator Debarment Checks: What Sponsors Must Verify Before a Trial Starts
The FDA can debar individuals from working on regulated drug applications, and using a debarred investigator can sink a study's data. This article explains the debarment check: the legal basis, the lists to search, and how to document the results.
Master Protocols Explained: Basket, Umbrella, and Platform Trials
Master protocols let one trial test many treatments at once. This article explains basket trials, umbrella trials, and platform trials, how they cut costs and speed up results, and the statistical and operational challenges they bring.
Non-inferiority trials: when good enough is good enough
Non-inferiority trials ask whether a new treatment is not too much worse than the current standard, within a pre-specified margin. Here is how the delta margin, confidence intervals, and ICH E10 shape these studies.
Orphan Drugs and Rare Disease Trials: Hope for Millions
Before 1983, only a handful of treatments existed for rare diseases. The Orphan Drug Act changed that. Here's how incentives, innovation, and patient advocacy are bringing treatments to people with rare conditions.
Participation burden: what a clinical trial really asks of patients
Frequent visits, blood draws, daily diaries, travel, lost wages, childcare. Participation burden is a leading reason people drop out of clinical trials, and it is something researchers can reduce.
The Patient Journey Through a Clinical Trial: What to Expect
From finding a trial to completing the last follow-up visit, the patient journey through a clinical trial has six phases. This article walks through screening, informed consent, randomization, treatment, monitoring, and follow-up, and explains what patients should expect at each step.
Patient-Reported Outcomes: The Patient's Voice in Clinical Research
No lab test, scan, or physician assessment can substitute for the patient's own experience. Here's how patient-reported outcomes (PROs) work and why they shape drug approvals.
Pharmaceutical Patents and Intellectual Property: How Drug Companies Protect Their Work
Patents, data exclusivity, and trade secrets decide who can sell a drug, for how long, and at what price. Here is how pharmaceutical intellectual property works, from the patent cliff to generic competition.
The Pregnancy Paradox: Why Most Drugs Prescribed During Pregnancy Were Never Tested in Pregnancy
Millions of pregnant women take prescription drugs every year, yet fewer than 1% of approved drugs have adequate pregnancy safety data from trials. This article explains how that gap formed, why exclusion has its own costs, and how regulators and researchers are working to close it.
Publication Bias in Clinical Research: The Problem of Unreported Results
Roughly half of all completed clinical trials never get published, and studies with positive results are far more likely to see the light of day. Here is how publication bias distorts medicine and what is being done about it.
Randomized Controlled Trials Explained: Why They're the Gold Standard
Why can't doctors just choose who gets the new treatment? Because human judgment contaminates the results. Here's how randomization and control groups make medical evidence trustworthy.
RCT vs Real-World Evidence: Two Ways to Know If a Treatment Works
Randomized controlled trials and real-world evidence answer different questions about a treatment: can it work under ideal conditions, and does it work in everyday practice? Here is how the two compare and why regulators now use both.
Site Selection in Clinical Research: How Sponsors Pick the Right Investigative Sites
Site selection decides whether a clinical trial enrolls on time and produces clean data. This article walks through feasibility, investigator qualification, infrastructure checks, and the scoring frameworks sponsors use to build a winning site portfolio.
Site Start-Up in Clinical Trials: From Feasibility to First Subject Enrolled
Site start-up covers everything between picking an investigator and enrolling the first subject: feasibility, regulatory documents, IRB approval, contracts, and the site initiation visit. Here is how the process works and where delays creep in.
Synthetic Control Arms: What If a Clinical Trial Didn't Need a Placebo Group?
Synthetic control arms replace a placebo group with historical patient data. They cut enrollment by up to half, save tens of millions of dollars, and make trials possible in rare diseases where placebo controls are unethical. This article explains how they work, their limits, and the approvals they have already supported.
Understanding Decentralized Clinical Trials: Research That Comes to the Patient
Decentralized clinical trials move study visits out of the clinic and into the patient's life: video visits, home health nurses, direct-to-patient drug delivery, and wearables. This article explains how they work, what regulators say, and why they are here to stay.
FDA Form 1572 Explained: The Statement of Investigator
FDA Form 1572, the Statement of Investigator, is the signed commitment between a clinical investigator and the FDA. This article explains every section, when it must be updated, and why errors here are a common inspection finding.
What Does a CRO Do? Contract Research Organizations Explained
If a pharmaceutical company discovers a promising drug, how do they test it on thousands of patients across dozens of countries? They hire a CRO. Here's what contract research organizations actually do.
What Is a Clinical Trial Protocol? The Blueprint of Every Clinical Study
The protocol is the master document of any clinical trial: who can enroll, what treatment they get, and how the data is judged. Here is how protocols are built, reviewed, and amended.
What Is a Clinical Trial?
Every medicine you have ever taken started its journey in a clinical trial. Here's what a clinical trial actually is, how the four phases work, and how participants are protected.
What Is GCP? Good Clinical Practice Explained Simply
Good Clinical Practice (ICH E6) is the international quality standard behind every clinical trial. This article explains the 13 GCP principles, who is responsible for what, and what happens when the rules are broken.
Why 80% of Clinical Trials Can't Find Enough Patients
Up to 80% of clinical trials fail to enroll enough patients on time. The barriers are stacked: narrow criteria, low awareness, travel burden, mistrust, and more. Here's the full picture and what's being done about it.
Why Clinical Trials Happen All Over the World: Globalization Explained
Drug companies run trials in dozens of countries at once, and it is not just about saving money. Here is why global trials happen, how they are regulated, and the ethical questions they raise.
Why Clinical Trials Use Sugar Pills (and Why It Matters for Your Health)
Can a sugar pill really heal you? The placebo effect is a real psychobiological event, powerful enough that every clinical trial must control for it. Here's how it works.
Why Diversity in Clinical Trials Matters More Than You Think
Drugs work differently across populations, but trials have historically enrolled narrow, homogeneous groups. Diversity in clinical trials is a scientific necessity, not a checkbox, and regulators now require it.
Why Are Drugs So Expensive? The $2.6 Billion Cost of Drug Development
The often-cited $2.6 billion price tag for developing a new drug sounds unbelievable. Here's what that number actually covers, where the money goes, and why it matters for patients.